«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 15

Page:

2884-2890

Research Field:

Publishing date:

Info

Title:

Comparative analysis of clinical and laboratory characteristics of patients with different types of secondary acute myeloid leukemia

Author(s):

JIANG Yanhong¹; WANG Hao¹; BI Lijun²; XU Qingxia¹

1.Department of Clinical Laboratory,the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Zhengzhou Key Laboratory of Digestive Tumor Markers,Henan Zhengzhou 450008,China;2.Institute of Biophysics,Chinese Academy of Sciences,Guangdong Foshan 528000,China.

Keywords:

secondary; myelodysplastic syndrome; treatment-related; acute myeloid leukemia

PACS:

R733.71

DOI:

10.3969/j.issn.1672-4992.2023.15.022

Abstract:

Objective:To compare and analyze the clinical and laboratory characteristics of patients with different types of secondary acute myeloid leukemia.Methods:The laboratory and clinical data of 75 patients with secondary acute myeloid leukemia (s-AML) in the department of hematology,Henan Cancer Hospital from January 2014 to December 2021 were retrospectively analyzed,and they were divided into t-AML group and MDS-AML group.The laboratory and clinical data were obtained by consulting the electronic medical record system and the laboratory data management system.SPSS 25.0 software was used for data analysis.Results:Compared with patients in t-AML group,the proportion of females,onset interval,proportion of bone marrow blasts,proportion of abnormal chromosomes,proportion of fusion gene,proportion of APL patients,proportion of CR patients,OS and RFS were lower in MDS-AML group(statistical values:9.471,280.000,275.00,7.440,2.266,8.049,5.489,4.125 and 6.316,P values:0.002,0.000,0.000,0.006,0.000,0.005,0.019,0.042 and 0.012,all P values<0.05),and the difference was statistically significant.MDS-AML was a risk factor for OS and RFS in s-AML patients(statistical values:4.145 and 10.029,P values:0.042 and 0.002,all P values<0.1),and the difference was statistically significant,but not an independent risk factor(HR:0.886 and 0.481,P values:0.809 and 0.504,all P values>0.05),and the difference was not statistically significant.Conclusion:MDS-AML patients have poorer treatment outcomes and poorer prognosis compared with t-AML patients.

References:

£Û1£ÝZHOU F,ZHOU F,DU M,et al.Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients£ÛJ£Ý.Int J Hematol,2019,110(5):575-583.
£Û2£ÝKHOURY JD,SOLARY E,ABLA O,et al.The 5th edition of the world health organization classification of haematolymphoid tumours:Myeloid and histiocytic/dendritic neoplasms£ÛJ£Ý.Leukemia,2022,36(7):1703-1719.
£Û3£ÝSTRICKLAND SA,VEY N.Diagnosis and treatment of therapy-related acute myeloid leukemia£ÛJ£Ý.Crit Rev Oncol Hematol,2022,171:103607.
£Û4£ÝWONG TN,RAMSINGH G,YOUNG AL,et al.Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia£ÛJ£Ý.Nature,2015,518(7540):552-555.
£Û5£ÝTAKAHASHI K,WANG F,KANTARJIAN H,et al.Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms:a case-control study£ÛJ£Ý.Lancet Oncol,2017,18(1):100-111.
£Û6£ÝBHATIA S.Therapy-related myelodysplasia and acute myeloid leukemia£ÛJ£Ý.Semin Oncol,2013,40(6):666-675.
£Û7£ÝFALINI B,MARTELLI MP.Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia£ÛJ£Ý.Am J Hematol,2023,98(3):481-492.
£Û8£Ý¾£Óñæã¬ÕÔÑ޺죬Öܽú.¹ÇËèÔöÉúÒì³£×ÛºÏÕ÷µÄÃâÒßÒì³£¼°ÖÎÁƽøÕ¹£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ£¬2021,29£¨21£©£º3874-3877. JING YT,ZHAO YH,ZHOU J.Immunity abnormalities and treatment progress of myelodysplastic syndrome£ÛJ£Ý.Modern Oncology,2021,29£¨21£©£º3874-3877.
£Û9£ÝHOSPITAL MA,VEY N.Myelodysplastic syndromes:How to recognize risk and avoid acute myeloid leukemia transformation£ÛJ£Ý.Curr Oncol Rep,2020,22(1):4.
£Û10£ÝBEJAR R.What biologic factors predict for transformation to AML£ÛJ£Ý.Best Pract Res Clin Haematol,2018,31(4):341-345.
£Û11£ÝÇس¿è¡,¸Ê˼ÁÖ,Íò¶¦Ãú,µÈ.¹ÇËèÔöÉúÒì³£×ÛºÏÕ÷ת»¯µÄ¼±ÐÔËèϵ°×Ѫ²¡52ÀýÁÙ´²¹Û²ì£ÛJ£Ý.°×Ѫ²¡¡¤ÁÜ°ÍÁö,2016,25(5):290-294. QIN CC,GAN SL,WAN DM,et al.Clinical observation of 52 patients with acute myeloid leukemia transformed from myelodysplastic syndrome£ÛJ£Ý.Journal of Leukemia and Lymphoma,2016,25(5):290-294.
£Û12£Ý¶ÎÓñˬ.¹ÇËèÔöÉúÒì³£×ÛºÏÕ÷ת»¯Îª¼±ÐÔËèϵ°×Ѫ²¡»¼ÕßµÄÁÙ´²ÌØÕ÷¼°Ô¤ºó·ÖÎö£ÛD£Ý.Ì«Ô­£ºÉ½Î÷Ò½¿Æ´óѧ,2017. DUAN YS.The clinical characteristics and prognosis of patients with acute myeloid leukemia evolving from myelodysplastic syndrome£ÛD£Ý.Taiyuan:Shanxi Medical University,2017.
£Û13£Ý¬ç²Ë¼,ÐíÄÈ,ÖÜè¯,µÈ.35ÀýÖÎÁÆÏà¹ØѪҺÖ×Áö»¼ÕßµÄÁÙ´²ÌØÕ÷¼°Ô¤ºó·ÖÎö£ÛJ£Ý.ÖлªÑªÒºÑ§ÔÓÖ¾,2016,37(3):221-226. LU QS,XU N,ZHOU X,et al.Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms£ÛJ£Ý.Chinese Journal of Hematology,2016,37(3):221-226.
£Û14£ÝESP¦PRITO SANTO AE,CHACIM S,FERREIRA I,et al.Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia£ÛJ£Ý.Oncol Lett,2016,12(1):262-268.
£Û15£ÝÎâæÂæÂ,»ÆÁÕ,ÓÚÖ¥Ó±,µÈ.»¯ÁÆÒ©ÎïÖÂÖÎÁÆÏà¹ØÐÔ°×Ѫ²¡94ÀýÁÙ´²Ìص㼰·ÖÎö£ÛJ£Ý.ÖйúҽԺҩѧÔÓÖ¾,2016,36(7):578-581. WU YY,HUANG L,YU ZY,et al.Analysis of clinical characteristics of 94 patients with leukemia caused by chemotherapy drugs£ÛJ£Ý.Chinese Journal of Hospital Pharmacy,2016,36(7):578-581.
£Û16£ÝKOTINI AG,CHANG CJ,CHOW A,et al.Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia£ÛJ£Ý.Cell Stem Cell,2017,20(3):315-328.
£Û17£ÝADAMSKA M,KOWAL-WISNIEWSKA E,PRZYBY¢rOWICZ-CHALECKA A,et al.Clinical outcomes of therapy-related acute myeloid leukemia:an over 20-year single-center retrospective analysis£ÛJ£Ý.Pol Arch Intern Med,2023,133(1):16344.
£Û18£ÝWOLFF AC,BLACKFORD AL,VISVANATHAN K,et al.Risk of marrow neoplasms after adjuvant breast cancer therapy:the national comprehensive cancer network experience£ÛJ£Ý.J Clin Oncol,2015,33(4):340-348.
£Û19£ÝLARSON RA.Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia£ÛJ£Ý.Best Pract Res Clin Haematol,2007,20(1):29-37.
£Û20£ÝDE SOUZA DC,FERNANDEZ CDE S.Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome£ÛJ£Ý.Biomed Res Int,2014,2014:542395.
£Û21£ÝKOTSIAFTI A,GIANNAKAS K,CHRISTOFOROU P,et al.Progress toward better treatment of therapy-related AML£ÛJ£Ý.Cancers (Basel),2023,15(6):1658.
£Û22£ÝCHURPEK JE,MARQUEZ R,NEISTADT B,et al.Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia£ÛJ£Ý.Cancer,2016,122(2):304-311.
£Û23£ÝNAKAJIMA H.Molecular pathogenesis and treatment of myelodysplastic syndromes£ÛJ£Ý.Intern Med,2021,60(1):15-23.
£Û24£ÝDESAI P,MENCIA-TRINCHANT N,SAVENKOV O,et al.Somatic mutations precede acute myeloid leukemia years before diagnosis£ÛJ£Ý.Nat Med,2018,24(7):1015-1023.
£Û25£ÝFELDMAN EJ.Does therapy-related AML have a poor prognosis,independent of the cytogenetic/molecular determinants£ÛJ£Ý.Best Pract Res Clin Haematol,2011,24(4):523-526.
£Û26£ÝFIANCHI L,PAGANO L,PICIOCCHI A,et al.Characteristics and outcome of therapy-related myeloid neoplasms:Report from the Italian network on secondary leukemias£ÛJ£Ý.Am J Hematol,2015,90(5):80-85.
£Û27£ÝYAKOUB-AGHA I,DE LA SALMONI¦KRE P,RIBAUD P,et al.Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia:a long-term study of 70 patients-report of the French society of bone marrow transplantation£ÛJ£Ý.J Clin Oncol,2000,18(5):963-971.
£Û28£ÝMONTALBAN-BRAVO G,GARCIA-MANERO G.Myelodysplastic syndromes:2018 update on diagnosis,risk-stratification and management£ÛJ£Ý.Am J Hematol,2018,93(1):129-147.
£Û29£ÝGUILLAUME T,MALARD F,MAGRO L,et al.Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome£ÛJ£Ý.Bone Marrow Transplant,2019,54(11):1815-1826.
£Û30£ÝZHANG L,WANG SA.A focused review of hematopoietic neoplasms occurring in the therapy-related setting£ÛJ£Ý.Int J Clin Exp Pathol,2014,7(7):3512-3523.

Memo

Memo:

National Natural Science Foundation of China(No.82203572£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¨±àºÅ£º82203572£©

Common functions

Last Update: 2023-06-30